← Retour au Screener

Sector: Santé
Open in Terminal → SEERLive chart · Key metrics · News · Smart money

Seer Bio

SEER Micro Cap

Healthcare · Biotechnology

Mis à jour: Aug 2, 2026, 22:14 UTC

1,93 €
+7.77% aujourd'hui
52W: 1,35 € – 2,09 €
52W Low: 1,35 € Position: 77.9% 52W High: 2,09 €

Price Chart

Indicateurs clés

P/E Ratio
Cours/Bénéfice
Forward P/E
P/E prévisionnel
P/S Ratio
8.05x
Cours/Ventes
EV/EBITDA
0.32x
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
106 M €
Capitalisation boursière
Croissance du CA
-33.6%
Croissance du CA sur un an
Marge bénéficiaire
Marge nette
ROE
-25.52%
Rentabilité des capitaux propres
Beta
1.59
Sensibilité au marché
Positions vendeuses
0.3%
% du flottant vendu à découvert
Volume moyen
1,085,595
Volume quotidien moyen

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
None
1 analysts
Avg. Price Target
3,48 €
+80.18% upside
Target Range
3,48 € – 3,48 €

About the Company

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 124 Exchange: NMS

Seer Bio en bref

Seer Bio (SEER) is currently trading at 1,93 € with a market capitalization of 106 M €. The 52-week range spans from 1,35 € to 2,09 €; the current price is 7.9% below the yearly high. Year-over-year revenue growth stands at -33.6%.

💰 Dividende

Seer Bio currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

1 analystes évaluent Seer Bio (SEER) au consensus : None. L'objectif de cours moyen est de 3,48 €, soit un potentiel de +80.18% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 3,48 € à 3,48 €.

Seer Bio : la thèse d'investissement en détail

Seer Bio (SEER) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario baissier

Revenue is contracting at -33.6% year-over-year — until that trend reverses, valuation is exposed to further downgrades.

Valorisation en contexte

The EV/EBITDA multiple of 0.32x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

  • The analyst consensus price target implies 80.18% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Points forts
  • Bilan solide avec faible endettement (D/E 9.54)
Points faibles
  • CA en contraction (-33.6% sur un an)
  • Free cash flow négatif

Aperçu technique

MM 50 jours
1,65 €
+16.84% vs. cours
MM 200 jours
1,66 €
+16.23% vs. cours
Sous le plus haut 52s
−7.9%
2,09 €
Au-dessus du plus bas 52s
+43.2%
1,35 €

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

Risque de marché (Bêta)
1.59 · Élevé
Évolue plus que le marché global
Positions vendeuses
0.3% · Faible
% du flottant vendu à découvert
Dette/Capitaux propres
9.54 · Faible
Dette totale / capitaux propres

The data points to above-average price swings.

Trading Data

50-Day MA: 1,65 €
200-Day MA: 1,66 €
Volume: 2,903,582
Avg. Volume: 1,085,595
Short Ratio: 0.07
P/B Ratio: 0.51x
Debt/Equity: 9.54x
Free Cash Flow: -27 526 823 €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy Seer Bio?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut